Overview

Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis

Status:
Terminated

Trial end date:
2009-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to establish single-dose tolerability of inhaled treprostinil sodium in idiopathic pulmonary fibrosis (IPF) patients with pulmonary hypertension, and to explore the acute hemodynamic effects over a range of tolerable doses. The safety and pharmacodynamic information obtained from this study will inform the design and conduct of future studies in inhaled treprostinil sodium in this population.

Phase:

Phase 2

Details

Lead Sponsor:

Lung Biotechnology PBC

Treatments:

Treprostinil